Literature DB >> 20937667

Endothelial, sympathetic, and cardiac function in inherited (6R)-L-erythro-5,6,7,8-tetrahydro-L-biopterin deficiency.

Lila Mayahi1, Lydia Mason, Katherine Bleasdale-Barr, Ann Donald, Iris Trender-Gerhard, Mary G Sweeney, Mary B Davis, Nicholas Wood, Christopher J Mathias, Laura Watson, Denis Pellerin, Simon Heales, John E Deanfield, Kailash Bhatia, Judith Murray-Rust, Aroon D Hingorani.   

Abstract

BACKGROUND: (6R)-5,6,7,8-Tetrahydro-l-biopterin (BH4) is a cofactor for enzymes involved in catecholamine and nitric oxide generation whose synthesis is initiated by GTP cyclohydrolase I (GTPCH-1), encoded by GCH1. In the absence of a potent, specific GTPCH-1 inhibitor, natural BH4 deficiency caused by mutations in GCH1 in the rare movement disorder, DOPA-responsive dystonia (OMIM DYT5), offers the opportunity to study the role of endogenous BH4 in humans. METHODS AND
RESULTS: In 16 DOPA-responsive dystonia patients with mutations predicted to affect GTPCH-1 expression or function and in age- and sex-matched control subjects, we measured plasma biopterin and nitrogen oxides by high-performance liquid chromatography and the Griess reaction, respectively, endothelial function by brachial artery flow-mediated dilation (FMD), sympathetic function by measurement of plasma norepinephrine, epinephrine, and heart rate and blood pressure in response. Cardiac function and structure were assessed by echocardiography. Plasma biopterin was lower in patients (5.76±0.53 versus 8.43±0.85 nmol/L, P=0.03), but plasma NO(2)(-)/NO(3)(-) (NOx) (median, 9.06 [interquartile range, 5.35 to 11.04] versus 8.40 [interquartile range, 5.28 to 11.44] μmol/L, P=1) and FMD were not lower (7.7±0.8% versus 7.9±0.9%, P=0.91). In patients but not control subjects, FMD was insensitive to nitric oxide synthase inhibition (FMD at baseline, 6.7±2.1%; FMD during l-NMMA infusion, 6.2±2.5, P=0.68). The heart rate at rest was higher in patients, but the heart rate and blood pressure response to sympathetic stimulation did not differ in patients and control subjects despite lower concentrations of norepinepherine (264±8 pg/mL versus 226±9 pg/mL, P=0.006) and epinephrine (33.8±5.2 pg/mL versus 17.8±4.6 pg/mL, P=0.03) in patients. There was also no difference in cardiac function and structure.
CONCLUSIONS: Sympathetic, cardiac, and endothelial functions are preserved in patients with GCH1 mutations despite a neurological phenotype, reduced plasma biopterin, and norepinepherine and epinephrine concentrations. Lifelong endogenous BH4 deficiency may elicit developmental adaptation through mechanisms that are inaccessible during acquired BH4 deficiency in adulthood.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937667     DOI: 10.1161/CIRCGENETICS.110.957605

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  6 in total

1.  GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia.

Authors:  Zheng Fan; Robert Greenwood; Ana C G Felix; Yael Shiloh-Malawsky; Michael Tennison; Myra Roche; Kristy Crooks; Karen Weck; Kirk Wilhelmsen; Jonathan Berg; James Evans
Journal:  J Neurol       Date:  2014-02-08       Impact factor: 4.849

2.  Heterogenous vasodilator pathways underlie flow-mediated dilation in men and women.

Authors:  Beth A Parker; Michael E Tschakovsky; Amanda L Augeri; Donna M Polk; Paul D Thompson; Francis J Kiernan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-03       Impact factor: 4.733

3.  Assessments of arterial stiffness and endothelial function using pulse wave analysis.

Authors:  Lee Stoner; Joanna M Young; Simon Fryer
Journal:  Int J Vasc Med       Date:  2012-05-14

4.  Time estimation and arousal responses in dopa-responsive dystonia.

Authors:  Leonie F Becker; Sinem Tunc; Julius Verrel; Alexander Münchau; Peter Murphy; Tobias Bäumer; Anne Weissbach; Martje G Pauly; Duha M Al-Shorafat; Gerard Saranza; Anthony E Lang; Christian Beste; Tobias H Donner
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

Review 5.  Nonmotor Symptoms in Dopa-Responsive Dystonia.

Authors:  Elena Antelmi; Maria Stamelou; Rocco Liguori; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2015-07-22

6.  Regulation of β-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin.

Authors:  David Adlam; Neil Herring; Gillian Douglas; Joseph P De Bono; Dan Li; Edward J Danson; Amy Tatham; Cheih-Ju Lu; Katie A Jennings; Stephanie J Cragg; Barbara Casadei; David J Paterson; Keith M Channon
Journal:  Cardiovasc Res       Date:  2012-01-11       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.